Pierre Fabre and Roche extend collaboration agreement on companion diagnostic development

22-May-2018 - Pierre Fabre announced today the extension of a collaboration agreement with Roche on companion diagnostic development for W0101, Pierre Fabre's new antibody drug conjugate (ADC) product candidate targeting Insulin-like Growth Factor 1 (IGF-1) receptor currently in the international Phase I/II ...

Horizon Discovery Group and Ventana Medical Systems sign co-development agreement

02-Sep-2016 - Horizon Discovery Group plc announces it has entered into a co-development and commercialisation agreement with Ventana Medical Systems, Inc., a member of the Roche Group. The Agreement covers the development, manufacture and commercialisation of cell line derivative materials for use as IHC ...

Ventana announces collaboration to develop companion diagnostics for ImmunoGen's targeted anticancer agents

30-Oct-2014 - Ventana Medical Systems, Inc. announced it has entered into an agreement with ImmunoGen, Inc. to collaborate on the development of biomarker assays and a companion diagnostic immunohistochemistry (IHC) test for one or more of ImmunoGen's product candidates. Under this agreement, the companies ...

Ventana and MedImmune collaborate to develop immunohistochemistry assay

10-Jun-2014 - Ventana Medical Systems, Inc. and MedImmune announced they are jointly developing a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune's MEDI4736 anti-PD-L1 therapy for non-small cell lung carcinoma. This includes the recently commenced MEDI4736 ATLANTIC ...

Frost & Sullivan determines a real and urgent need for novel cancer diagnostics tests

Nucleic acid based tests address the need for tests that aid in the early detection and prevention of cancer

06-Feb-2013 - The range of potential therapeutic approaches available to treat cancer is expected to expand rapidly during the next decade. Current diagnostic technologies focus on detection and diagnosis of cancer using mainly blood, faeces, urine tests or genetic tests. Testing methods are now gradually ...

Clavis Pharma Licenses Rights to hENT1 antibody to Ventana Medical Systems, Inc.

04-May-2010 - Clavis Pharma ASA announced that it has entered into a licence agreement with Ventana Medical Systems, Inc. providing Ventana with exclusive access to Clavis Pharma’s monoclonal antibody targeting human nucleoside transporter 1 (hENT1) and to the hybridoma cell line that produces the antibody. ...

Olink Bioscience and Olink Genomics in a project aimed to improve cancer treatment

15-Sep-2009 - Olink Bioscience and its sister company Olink Genomics is participating in the project "Companion Diagnostics Initiative" which is financed by Vinnova and aims to develop improved cancer diagnostics to increase survival rate of patients with colorectal cancer. The project is coordinated by ...

Olink Bioscience and AH diagnostics sign distributorship agreement for the Danish and Norwegian markets

19-Aug-2009 - Olink Bioscience has signed a distributorship agreement with AH diagnostics for distribution of the Duolink® in situ PLA™ product line in Denmark and Norway. “AH diagnostics has a strong presence on the molecular biology and immunology markets in Denmark and Norway and with its focus on ...

Novel Diagnostics Methods Driving the European Cancer IVD Market towards Early Detection and Prevention

26-Feb-2009 - Early detection is the key focus of cancer diagnostics. Traditional testing methods such as immunoassay testing are facing fierce competition from evolving segments such as nucleic acid amplification technology (NAT) and immunohistochemistry testing. The ability to prove the clinical utility and ...

Avontec announces the results of a successful proof of concept within a phase 2a study with its drug candidate AVT-02 UE

15-Oct-2008 - Avontec GmbH announced the results of a multicenter, randomized, double-blind, placebo-controlled, intra-individual-comparison phase 2a trial to evaluate the efficacy and safety of 2% AVT-02 UE ointment in the treatment of mild to moderate psoriasis vulgaris. The phase IIa study enrolled 60 male ...